ITRS-GROUP
1.6.2022 10:02:12 CEST | Business Wire | Press release
ITRS Group, leading provider of real-time enterprise monitoring and analytics software to global financial institutions, today announces the launch of its newest product offering, Obcerv.
Amidst rapid digital transformation, modern IT operations have evolved from a traditional on-premises system to increasingly complex hybrid cloud environments. Traditional monitoring no longer addresses the complexities of the modern IT services stack and firms face a growing challenge to centralise data monitoring that can enhance performance, reveal patterns and trends in resource utilisation, and reduce outages.
The launch of Obcerv will introduce end-to-end visibility into infrastructure and applications, and through intelligent alert aggregation, it will identify the most likely source of a problem, enabling users to improve service delivery. Obcerv will act as both a data storage and analytics platform for critical monitoring, allowing users to gain full visibility and ultimately take back control of their systems.
Obcerv simplifies and accelerates traditionally complex monitoring systems with benefits including but not limited to:
- The intelligent correlation of data from multiple data feeds and streams to simplify analysis
- Data compression minimises storage costs, without having to aggregate the data as many tools do, ensuring data fidelity is maintained
- Root cause analysis is accelerated, offering alerts based on commonality, thereby providing context and meaning to alerts
- Unique APIs facilitate full interoperability, Obcerv can store data from other ITRS Group products, but from monitoring tools from other vendors too
Guy Warren, CEO of ITRS Group, said: “Monitoring is often seen as the canary in the coal mine: it may be able to tell you that something is wrong, but too often the message lacks context and meaning. Obcerv will provide IT operators with an understanding around why certain things happen, allowing them to accurately decide the best course of action.
In recent years, modern IT estates have become extremely complex, pushing many monitoring teams to the edge of their capability, leaving them struggling to deliver on uptime and reliability metrics. And with more than half of all firms experiencing at least a day of downtime each year, it is clear that monitoring solutions that are able to match the increasing complexities of the systems they are monitoring is required. Obcerv will not only help firms to gain full visibility across their estates but in doing so, it will enable them to regain control of them.”
For more information, visit www.itrsgroup.com/products/obcerv
About ITRS Group
ITRS Group ensures operational resilience for enterprises engaged in transforming their IT estate for a digital future, as well as the ongoing health of their on-premise, cloud-based or hybrid IT estate. By transforming the mass of raw data on performance, resource usage, and cost, ITRS Group’s solutions can detect and actively prevent problems and maximise cost efficiency, reassuring enterprises that their IT estates are running effectively. With experience in legacy technologies as well as the dynamic environment of cloud-delivery, agile development, and service-based architecture, ITRS Group’s people and software serve more than 4500 clients across industry markets. As new disruptors, new technologies, and new regulations continue to shape the marketplace and change the expectations of consumers, ITRS Group offers a best-in-class service and is a source of confidence for the always-on enterprise.
For more information, visit www.itrsgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
